N/A
Completed N=47
Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety
Social Intelligence
Source: ClinicalTrials.gov NCT01551303 ↗
Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcomePrimary: Affective Ratings in Affective Learning Task — -0.096; -0.12 units on a scale
Summary
The purpose of this study is to learn more about how emotional processing may be affected by a hormone called oxytocin. Oxytocin is a hormone that occurs naturally in the body, and may play an important role in the way that the brain perceives information.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Affective Ratings in Affective Learning Task |
-0.096; -0.12 | — |
Eligibility Criteria
Inclusion Criteria
- No current Axis I according to Diagnostic & Statistical Manual for Psychiatry-IV excluded diagnoses as determined by MINI or Structured Clinical Interview for Diagnosis psychiatric diagnostic interview completed within the past 6 months
- Age 18 to 65
- Subjects must be able to give informed consent and be willing and able to comply with study procedures.
Exclusion Criteria
- Patients with severe unstable medical illness, clinically significant laboratory findings, or serious medical illness for which hospitalization may be likely within the next three months
- Pregnant or lactating women.
- Subjects currently taking hormones, such as estrogen.
- Known hypersensitivity to oxytocin or to any of the excipients of Syntocinon Nasal spray.
- Known hyponatremia or concurrent use of diuretics.
- Subjects with a history of seizure disorder.
Data sourced from ClinicalTrials.gov (NCT01551303). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.